SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants.

Hannes LindahlPuran ChenMikael ÅbergHans-Gustaf LjunggrenMarcus BuggertSoo AlemanC I Edvard SmithPeter Bergman

Published in: Journal of clinical immunology (2023)

Commercial Ig batches currently contain large quantities of SARS-CoV-2 vaccine-induced antibodies. Cross-reactivity with variant strains is evident but varies, with markedly low neutralizing potential observed against Omicron variants.

Keyphrases

sars cov
copy number
respiratory syndrome coronavirus
escherichia coli
diabetic rats
high glucose
drug induced
oxidative stress
gene expression
climate change